AC Immune SA
ACIU
$1.77
-$0.11-5.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 31.52M | 46.94M | 17.48M | 16.72M | 16.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.52M | 46.94M | 17.48M | 16.72M | 16.72M |
| Cost of Revenue | 71.01M | 69.58M | 66.88M | 63.15M | 60.80M |
| Gross Profit | -39.50M | -22.64M | -49.41M | -46.44M | -44.08M |
| SG&A Expenses | 19.59M | 19.63M | 19.22M | 18.28M | 17.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -161.00K | -546.00K | -983.70K | -1.29M | -1.65M |
| Total Operating Expenses | 90.45M | 88.67M | 85.12M | 80.14M | 76.18M |
| Operating Income | -58.93M | -41.73M | -67.64M | -63.43M | -59.46M |
| Income Before Tax | -57.22M | -44.59M | -68.10M | -61.65M | -60.14M |
| Income Tax Expenses | 3.40K | 1.10K | 4.50K | 7.80K | 11.00K |
| Earnings from Continuing Operations | -57.22 | -44.59 | -68.10 | -61.66 | -60.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.22M | -44.59M | -68.10M | -61.66M | -60.15M |
| EBIT | -58.93M | -41.73M | -67.64M | -63.43M | -59.46M |
| EBITDA | -57.24M | -39.98M | -65.84M | -61.59M | -57.60M |
| EPS Basic | -0.57 | -0.46 | -0.72 | -0.69 | -0.71 |
| Normalized Basic EPS | -0.36 | -0.29 | -0.45 | -0.43 | -0.44 |
| EPS Diluted | -0.58 | -0.46 | -0.72 | -0.69 | -0.71 |
| Normalized Diluted EPS | -0.36 | -0.29 | -0.45 | -0.43 | -0.44 |
| Average Basic Shares Outstanding | 398.77M | 385.52M | 370.39M | 355.46M | 339.70M |
| Average Diluted Shares Outstanding | 399.78M | 386.54M | 370.39M | 355.46M | 339.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
